UCB Aktie

184,15 EUR +3,55 EUR +1,97 %

15:39:22

STU

183,20 EUR +2,90 EUR +1,61 %

17:50:05

GVIE

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.33,99 Mrd. EUR

KGV34,29Div. Rendite0,51%

WKN852738

ISINBE0003739530

SymbolUCBJF

UCB Aktien News

Sortieren:Datum Meistgelesen

09.03.24PR NewswireFirst Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis

08.03.24PR NewswireBIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count

28.02.24PR NewswireUCB on Growth Path for a Decade Plus

03.01.24PR NewswireZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive

01.12.23PR NewswireUCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

14.11.23PR NewswireUCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

11.11.23PR NewswirePost Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)

10.11.23PR NewswireUCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023

01.11.23PR NewswireUCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Founda...

31.10.23PR NewswireNAYZILAM® (midazolam) Results Published in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

18.10.23PR NewswireBIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

18.10.23PR NewswireUCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis

13.10.23PR NewswireUCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

12.10.23PR NewswirePhase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

21.07.23PR NewswireUCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-mu...

27.06.23PR NewswireUCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

20.04.23PR NewswireUCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting

17.04.23PR NewswireUCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

24.03.23GlobeNewswireUCB Convening Notice to the General Meeting of theShareholders 2023

18.03.23PR NewswireBimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

16.03.23PR NewswireUCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa

18.01.23PR NewswireAnnals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

06.01.23PR NewswireUCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

09.12.22PR NewswireUCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

07.12.22PR NewswireThe Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

01.12.22PR NewswireUCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care

23.11.22PR NewswireEpilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)

14.11.22PR NewswireUCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

10.11.22PR NewswireBimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

08.11.22PR NewswireUCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022

26.09.22PR NewswireUCB U.S. HEADQUARTERS IN ATLANTA AWARDED PRESTIGIOUS LEED GOLD AND WELL PLATINUM CERTIFICATIONS

22.09.22PR NewswireUCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

07.09.22PR NewswireNew Three-Year Bimekizumab Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque Psoriasis

06.12.19ReutersBelgium's UCB says psoriasis drug beats AbbVie's Humira in trial

10.10.19ReutersUPDATE 1-Belgium's UCB to buy Ra Pharmaceuticals in $2.1 bln cash deal

10.10.19ReutersBelgium's UCB to buy Ra Pharmaceuticals for $2.1 bln

UCB News

UCB News: auf dieser Seite finden Sie alle UCB News und Nachrichten zur UCB Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch UCB News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um UCB News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.